Aptil

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aptil

Quick Facts

Property Description
Active ingredient Captopril
Form Oral Tablet
Pharmacological class Angiotensin-Converting Enzyme (ACE) Inhibitor
General purpose Management of high blood pressure and strain on the heart
Origin Synthetic, Small Molecule

What Type of Medication is Aptil?

Aptil is a prescription medication fundamentally classified as an Angiotensin-Converting Enzyme (ACE) Inhibitor, intended for oral administration. The medication is a single-ingredient product, containing Captopril as its sole active ingredient. Captopril belongs to the class of ACE inhibitors used to treat high blood pressure.

This antihypertensive agent is a synthetic Small Molecule that belongs to a crucial pharmacological class used in managing blood vessel resistance. Aptil is typically provided in the solid oral tablet dosage form, which allows for a stable and convenient route of administration. The unique chemical makeup of Captopril defines its capacity to influence the body’s circulatory regulation system, particularly for Adults requiring chronic blood pressure management.

What is the Purpose of an ACE Inhibitor Like Aptil?

The primary general purpose of Aptil is to regulate the body’s blood pressure and reduce strain on the heart muscle. By working as an ACE Inhibitor, the drug helps promote Systemic vasodilation, which is the relaxation and widening of blood vessels.

This essential action is fundamentally beneficial in supporting overall cardiovascular conditions and improving circulatory health. The medication helps to diminish the overall resistance in the blood vessels, leading to a measurable reduction of blood pressure. Its intended use is to lower blood pressure in patients with hypertension. For instance, it is often utilized as a foundational medicine in management plans targeting long-term arterial pressure stability.

How Does Captopril Differ from Similar Drugs?

Captopril is distinguished within its class because it is immediately pharmacologically active and is not a prodrug, meaning the body does not need to chemically modify it to begin its work. This rapid bioavailability contrasts with certain Analogues that require metabolic conversion within the liver to become effective.

The medication's solid oral tablet form is designed to deliver a measured quantity of the active substance to ensure sustained suppression of the Renin-Angiotensin-Aldosterone System (RAAS). This structural and pharmacological distinction allows Captopril to exert its direct inhibitory effect, offering a reliable approach to long-term management.

Regulatory References

  1. Captopril (oral route) - MedlinePlus Drug Information
  2. Captopril - LiverTox - NIH

What side effects are possible with Aptil?

Possible Side Effects and Safety Information

The safety profile for Aptil (Captopril) details adverse reactions based on official regulatory classifications, including frequency and the physiological systems affected.

Adverse Reaction Classification

The following effects are classified by frequency in regulatory documents:

Classification Examples of Reactions
Common (1-10 users in 100) Dry, persistent cough, taste disturbance, dizziness, nausea, and fatigue.
Uncommon (1-10 users in 1,000) Hypotension (low blood pressure), Angioedema (swelling of the face or throat), chest pain, and palpitations.
Rare to Very Rare Neutropenia/Agranulocytosis (blood cell disorders), acute renal failure, and Stevens-Johnson syndrome.

Adverse reactions are also grouped by System-Organ Class, affecting the Vascular System (e.g., hypotension, Raynaud's phenomenon), the Respiratory System (e.g., cough), and the Renal System (e.g., impaired function, proteinuria).

Serious Adverse Reactions and Safety Constraints

The official safety information highlights specific serious adverse reactions. Angioedema, a rapid swelling of the deep tissues, is a potentially life-threatening reaction explicitly documented in the regulatory label. Neutropenia, a severe drop in white blood cell count, is also recognized, particularly in patients with pre-existing kidney issues or certain autoimmune conditions.

Regulatory documents include high-level safety constraints. The medication is Contraindicated in individuals with a known history of Angioedema related to a previous ACE inhibitor treatment. Use is also formally restricted during the second and third trimesters of pregnancy due to recognized risks to the fetus. Furthermore, official safety notes indicate that hypotension may be more likely to occur at the initiation of treatment or during any change in the amount administered.

Overdose and Emergency Response

The official regulatory profile for Aptil (Captopril) overdose is dominated by severe cardiovascular effects. The primary documented manifestation is severe hypotension, a sharp and excessive drop in blood pressure, which may progress to shock, stupor, or lethargy. Other listed presentations include bradycardia (abnormally slow heart rate) and severe disturbances in serum electrolytes. Overdose is classified as potentially severe or life-threatening due to the risk of these systemic effects, including acute renal failure.

Regulatory documents mandate that any suspected overdose requires immediate medical attention and contact with emergency services. Hospitalization and placement under close supervision, preferably in an intensive care unit, are required. Patients must be placed in a supine position if hypotension occurs.

Management is strictly supportive and symptomatic, as no specific antidote is known. Officially described procedures to counteract the effects include volume repletion with intravenous normal saline. If ingestion was recent, initial steps such as gastric lavage and the administration of adsorbents may be initiated. Monitoring is critical and must include frequent assessment of blood pressure, serum electrolytes, and creatinine. Observation must continue for a minimum of 12 to 24 hours post-ingestion, and discharge must only occur after the complete resolution of symptoms.

Therapeutic Uses of Aptil

Quick Facts: Aptil's Therapeutic Domains

  • Targeted Use: Adults with primary immunoglobulin A nephropathy (IgAN).
  • Core Benefit: Reduction of proteinuria (protein in the urine).
  • Patient Status: Indicated for adults considered at risk for disease progression.

Aptil is approved for use in adults diagnosed with primary immunoglobulin A nephropathy (IgAN) who are at risk of their condition worsening. This medication is intended to support the management of this serious kidney disorder.

The primary therapeutic effect of Aptil is to help achieve a reduction of proteinuria, which refers to the level of protein found in the urine. Proteinuria is an established indicator in IgAN. Reducing these levels may be associated with supporting better outcomes for long-term renal health. The medication is an approved treatment option to manage this specific patient population. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trials.

Eligibility and Restrictions for Use

Aptil is permitted for use in adults who are eligible for its approved indications. However, official regulatory documents establish specific population restrictions and absolute prohibitions.


Contraindications and Eligibility Restrictions

Eligibility Status Population Restriction
CONTRAINDICATED Aptil is strictly forbidden for patients with a history of angioedema (severe swelling) related to any previous ACE inhibitor or with hereditary/idiopathic angioedema. Use is absolutely prohibited during the second and third trimesters of pregnancy. Co-administration with Neprilysin Inhibitors (e.g., sacubitril/valsartan) or with Aliskiren (in diabetic patients) is also contraindicated.
USE WITH CAUTION Use requires close medical supervision in patients with impaired renal or hepatic function, often necessitating a lower dosage. Patients who are volume or sodium depleted must be started on a very low initial dose. Use is generally not recommended during the first trimester of pregnancy and while breastfeeding, especially in the postpartum period.
AGE RESTRICTION Safety and efficacy are not fully established for children under six years of age. Older adults may require a lower initial dose due to the increased likelihood of reduced renal function.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define specific, high-level constraints for co-administration of Aptil (Captopril) with other products. Co-administration with Sacubitril/Valsartan is formally contraindicated and requires a mandatory 36-hour wash-out period when switching to or from Aptil. The combination with Aliskiren is also prohibited, but this restriction applies specifically to patients with diabetes mellitus or established moderate-to-severe renal impairment.

The interaction profile highlights pharmacodynamic risks associated with electrolyte balance. Co-administration with Potassium-sparing diuretics (e.g., Triamterene) or potassium supplements is documented to increase the risk of hyperkalemia due to additive effects. Other documented interactions include an increased risk of angioedema when combined with mTOR Inhibitors, and a potential loss of antihypertensive effect when co-administered with Nonsteroidal Anti-inflammatory Drugs (NSAIDs), which also increases the risk of renal dysfunction.

Regarding systemic exposure, Aptil reduces the renal clearance of Lithium, leading to increased serum concentrations of Lithium. Conversely, Antacids officially reduce Aptil’s own oral absorption. To mitigate this pharmacokinetic interaction with food, a mandatory timing constraint requires Aptil to be taken one hour prior to meals.

Mechanism of Action

Aptil is a small molecule that functions as a highly selective inhibitor of the enzyme Farnesyl Pyrophosphate Synthase (FPPS).

The drug molecule binds competitively to the pyrophosphate binding site on the FPPS enzyme. This interaction prevents the catalytic conversion of farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP).

The resulting depletion of these isoprenoid lipids is essential for post-translational modification (prenylation) of specific signaling proteins, including small GTPases, in the osteoclast. Inhibiting prenylation disrupts the cytoskeletal integrity of the osteoclast, leading to a failure of the cell to adhere to the bone surface and perform its bone-resorbing function.

The suppression of osteoclast activity by this intracellular cascade results in the modulation of the bone remodeling unit, shifting the cellular balance toward net bone formation.

Dosage and Administration Information

How to Use Aptil

Aptil is administered orally in the form of a scored tablet, which is taken by mouth. A key instruction for proper use involves its relationship to food: the dose must be taken on an empty stomach, specifically at least one hour before a meal, as food intake can reduce the absorption and availability of the active substance.

Due to its relatively short half-life, the medication is typically used on a divided dosing schedule, often requiring administration two or three times a day to maintain a consistent effect. Standard maintenance dosing for chronic conditions, such as managing proteinuria, is commonly 25 mg three times daily, though the maximum adult daily limit is 450 mg.

Dosing Adjustments and Titration

Treatment is initiated with a low starting dose and is subject to a protocol of gradual titration, where the amount is slowly increased over one-to-two-week intervals under medical supervision. There is a reduced initial daily dose for patients with renal impairment (reduced kidney function), with subsequent dose adjustments made in smaller increments. Similarly, lower starting amounts are generally advised for older adults.

This usage protocol centers on the need for a strict time-relationship to meals and adherence to a divided schedule. This procedural structure is intended to support the drug reaching its target concentrations while providing flexibility through titration to establish a stable long-term regimen, especially considering physiological differences such as renal function.

Recent Clinical Evidence

Research evidence / Overview of studies


Efficacy in Moderate-to-Severe Pain

Studies have evaluated whether the compound can influence patient outcomes in moderate-to-severe pain studies. Research focused on the drug's properties. Studies examined the timeframe of reported symptom change. Research investigated whether the combination of this drug with a non-opioid analgesic resulted in different outcomes compared to monotherapy. Studies in patients receiving the maximum dosage evaluated the duration and extent of change in pain scores within 24 hours. Research also included studies on specific administration conditions. Research also compared outcomes with older treatments; findings were varied.


Safety and Side Effects

Studies evaluated the general tolerability profile in most adults. The primary side effects documented in the studies were tracked. However, studies in patients with a history of liver disease raised concerns regarding serious liver damage. Research investigated the potential for liver damage. Studies evaluated whether the drug was associated with different outcomes regarding dependency compared to traditional narcotics.


Off-Label Investigations

Preliminary research has explored its use in chronic neuropathic pain. Research explored whether the compound could influence the management of chronic neuropathic pain.

Frequently Asked Questions (FAQ)

Common questions about Aptil (FAQ)

Q: Can you drink alcohol while taking Aptil, or should it be avoided?

A: Official regulatory documents indicate that consuming alcohol (ethanol) may have additive effects with Aptil in lowering blood pressure. This could increase the risk of common side effects like lightheadedness and fainting, especially when treatment begins. Discussing alcohol consumption with a healthcare provider is generally recommended.

Q: How quickly should I expect to feel the effects of Aptil?

A: While an initial reduction in blood pressure may be noticed relatively quickly, the full therapeutic effect of Aptil often takes time to become established. According to clinical pharmacology information, the full intended therapeutic benefit may be reached through gradual adjustment over several weeks as determined by a healthcare provider.

Q: How long does one dose of Aptil stay in your system?

A: Studies on the drug’s active ingredient (Captopril) show it has a relatively short half-life (the time it takes for half the drug to be removed from the body). Due to its relatively short half-life, a multiple-dose schedule is often prescribed by healthcare professionals to help maintain consistent drug concentration.

Q: Can Aptil cause sleep problems or changes in energy levels?

A: Regulatory documents list fatigue and dizziness as common side effects that can affect a person’s energy levels. However, common side effect classifications generally do not list sleep problems (such as insomnia) as a frequent adverse reaction.

Q: Is it normal to feel a little dizzy when you first start taking Aptil?

A: Dizziness is listed as a common side effect in the official safety profile. Regulatory notes also indicate that a drop in blood pressure (hypotension) is more likely to occur when treatment is first started or when the dose is changed, which is the underlying cause of dizziness.

Q: Does Aptil affect blood pressure or heart rate?

A: Aptil is an antihypertensive agent and is intended to reduce blood pressure. A potential side effect is a drop in blood pressure (hypotension). Additionally, changes in heart rhythm or pulse (palpitations) are also listed as a less common side effect in the adverse reaction classifications.

Q: How is Aptil eliminated from the body?

A: Official product information shows that the medication is primarily cleared from the body through the kidneys. This fact is reinforced by the requirement for patients with reduced kidney function to be started on a lower initial dose.

Q: Is it true that Aptil can cause weight gain or loss?

A: In regulatory documents detailing potential side effects, unexplained weight gain is noted as a possible sign of more serious underlying issues related to heart or kidney function. If a patient experiences significant, unexplained weight change, they should consult with a healthcare professional.

Q: What's the difference between the tablet and capsule forms of Aptil?

A: The official product information explicitly describes Aptil as being administered as a scored tablet for oral use. Information regarding a separate capsule form of this medication is not included in the primary regulatory description.

Q: Can children take Aptil, and is the dosage adjusted?

A: According to official prescribing information, the safety and efficacy of Aptil are not fully established for children under six years of age. For those who are prescribed Aptil, the dosage is determined by a healthcare provider, often based on factors like weight.

Q: Are there common skin reactions reported with Aptil?

A: Official regulatory safety information lists rash as a possible adverse reaction. Other serious skin conditions, although rare, are also included in the complete side-effect profile.

Q: How long after stopping Aptil does the medication leave the body?

A: While the exact time it takes for the body to fully clear the drug varies, a specific 36-hour wash-out period is required when switching to or from certain other types of medications. This specific timing is in place to allow the active ingredient to clear the system when transitioning to certain other medications.

Q: What happens if I accidentally take too much Aptil?

A: Regulatory information on overdosage suggests that taking too much Aptil can lead to severe hypotension (extremely low blood pressure) and other serious effects. In any suspected overdose situation, it is important to contact emergency services or a poison control center immediately.

Q: Are there any long-term side effects that are known for Aptil?

A: Studies evaluate the side-effect profile over time, detailing known adverse reactions in patients followed for several years. One common effect that can persist is a dry, persistent cough. Other effects are tracked based on their frequency over the course of treatment.

Q: Does Aptil interact with medications for diabetes or cholesterol?

A: Official product information highlights a formal prohibition against co-administration with the drug Aliskiren specifically in patients with diabetes mellitus. The label also notes that patients with diabetes have a higher chance of developing elevated potassium levels (hyperkalemia) while on Aptil.

Q: Why is Aptil sometimes prescribed in combination with other drugs?

A: Regulatory indications note that Aptil is often prescribed in combination with other medicines, such as diuretics, especially for managing conditions like congestive heart failure. This combination approach is used to enhance the overall benefit for the cardiovascular system.

Q: Can Aptil affect the results of any laboratory tests?

A: Official labeling confirms that Aptil can affect certain laboratory findings. This includes causing elevations in blood urea nitrogen (BUN) and serum creatinine, and it can also interfere with certain urine tests, potentially causing a false positive for acetone.

Q: Can you take Aptil if you have a history of stomach ulcers?

A: The official safety profile does not strictly prohibit use in patients with stomach ulcers. However, it does list gastrointestinal issues like nausea and abdominal pain as potential side effects. There are also reports of a rare but serious condition called intestinal angioedema (swelling of the intestine).

Q: Does the age of the patient affect how well Aptil works?

A: Official information indicates that older adults may require a lower starting dose primarily because they are more likely to have reduced kidney function, which affects how the drug is cleared from the body. This adjustment is for safety and tolerability rather than overall efficacy.

Q: Are there any public health warnings related to Aptil?

A: The most significant regulatory caution is a Boxed Warning regarding the risk of fetal toxicity. Official documents state that the use of Aptil during the second and third trimesters of pregnancy can cause injury and death to the developing fetus.

Q: Is there a dietary change recommended while taking Aptil?

A: Official patient information often highlights the importance of discussing high potassium dietary intake, such as salt substitutes, with a healthcare professional. This is because Aptil can cause an increase in potassium levels in the blood (hyperkalemia).

Q: Why does Aptil have a black box warning (if applicable - general question type)?

A: Aptil (Captopril) carries a Boxed Warning in the US regulatory label. This warning addresses the risk of fetal toxicity, stating that the medication can cause injury and death to a developing fetus when used during the second and third trimesters of pregnancy.

Q: Can Aptil cause changes in mood or anxiety?

A: While mood changes or anxiety are not explicitly listed in the common side-effect categories, other central nervous system (CNS) effects, such as headache, are listed as common adverse reactions in regulatory documents.

Q: Does Aptil interact with herbal teas or remedies?

A: The official label suggests that patients discuss the use of all other medications, vitamins, and herbs with their healthcare provider. Some herbal products or remedies, particularly those containing high levels of potassium, could pose a risk of interaction.

Q: Is it okay to cut or crush the Aptil tablet?

A: Aptil is supplied as a scored tablet, meaning it may be broken along the groove. It is important to confirm with a healthcare professional if any further manipulation, such as crushing, is appropriate for that specific formulation.

Q: What should I do if I miss a dose of Aptil?

A: Patient information generally provides specific guidance for handling a missed dose, typically advising patients to take the dose as soon as they remember, or to skip it if it is nearly time for the next one, and to avoid taking two doses at once. Patients are encouraged to review the official patient information leaflet or consult their pharmacist for detailed instructions.

Q: Can Aptil be taken with cold and flu medications?

A: Many over-the-counter cold and flu products contain drugs like Nonsteroidal Anti-inflammatory Drugs (NSAIDs), which can interact with Aptil. This interaction may potentially reduce Aptil's blood pressure-lowering effect and increase the risk of kidney-related issues. Therefore, discussing all over-the-counter medications with a healthcare provider is generally recommended.

How should Aptil be stored and disposed of?

How to Store and Dispose of Aptil?

Aptil (Captopril oral tablets) must be stored according to official regulatory specifications to maintain stability.

Storage Requirement Rule
Temperature Store at Room Temperature (20°C to 25°C / 68°F to 77°F).
Protection Keep away from excess heat, moisture, direct light, and do not freeze.
Container Keep the medication in its original container, tightly closed.

The medication must be stored out of the reach of children, securing the safety cap firmly.

To dispose of expired or unused Aptil, do not flush the tablets down the toilet. The preferred method is using a drug take-back program. If a program is unavailable, mix the medicine with an unappealing substance, seal it in a container, and throw it in the household trash. Always scratch out personal information from the label before disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Aptil found in:

A-Z Index: